Modern synthetic biology and AI represent both medicine’s greatest breakthrough and warfare’s most terrifying evolution. In this new landscape, where biological weapons can be designed faster than ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...
The average one-year price target for Genscript Biotech (OTCPK:GNNSF) has been revised to $3.32 / share. This is an increase of 16.00% from the prior estimate of $2.86 dated April 1, 2025. The price ...
Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering ...
The advent of mRNA vaccination, ignited by the COVID-19 pandemic, has sparked research to build the next generation of vaccine. Specifically, to address limitations of current mRNA vaccines—such as ...
It's quick and easy to access Live Science Plus, simply enter your email below. We'll send you a confirmation and sign you up for our daily newsletter, keeping you up to date with the latest science ...
Certain individuals with cancer were significantly more likely to survive if they received a COVID-19 mRNA vaccine, researchers at the University of Texas MD Anderson Cancer Center reported. This ...
The 2025 GenScript Virtual Summit—formerly the Gene and Cell Engineering Summit—serves as a leading international forum for scientists, biotech innovators, and pharmaceutical leaders to examine ...
We’re watching a new trend in semiconductor stocks concerning circular deals. Here’s why we think investors should be keeping an eye on it, though they shouldn’t be particularly worried at this point.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results